Related Experiment Videos
Gene therapy for Parkinson's disease: determining the genes necessary for optimal dopamine replacement in rat models
1Department of Neurology, University of Chicago, USA. u-kang@uchicago.edu
Abstract:
This article reviews the mechanism of dopamine delivery in the CNS in order to determine the optimal set of genes for effective gene therapy in Parkinson's disease (PD). Systematic neurobiological investigation of the biochemical steps has revealed that tyrosine hydroxylase (TH), which has been used in earlier studies, functions only when the essential cofactor, tetrahydrobiopterin (BH1) is present. Transduction of the gene for GTP cyclohydrolase I, the first and rate-limiting step in BH1 synthesis, along with the TH gene, generated cells that are capable of producing L-DOPA spontaneously both in vitro and in vivo. When the aromatic L-amino acid decarboxylase (AADC) gene was added as a third gene, in an attempt to increase the conversion of L-DOPA to dopamine, feedback inhibition by the end product, dopamine, on TH activity resulted. To circumvent this problem, we employed a complementary strategy. Gene transfer of the vesicular monoamine transporter was combined with AADC and produced genetically modified cells that can convert L-DOPA to dopamine and store it for gradual release. This approach provided a means to regulate final dopamine delivery by controlling precursor doses and to achieve more sustained delivery of dopamine. Our investigation into determining the genes necessary for optimal dopamine delivery has been facilitated by in vivo biochemical assays using microdialysis. This technique has provided us with a clear and quantitative tool to compare the effects of various genes involved in dopamine synthesis and processing.
Insights
Gene therapy for Parkinson's disease (PD) requires optimal dopamine delivery. Combining GTP cyclohydrolase I, tyrosine hydroxylase, and vesicular monoamine transporter genes offers a promising strategy for sustained dopamine production and release.
Area of Science:
- Neuroscience
- Molecular Biology
- Gene Therapy
Background:
- Parkinson's disease (PD) is characterized by dopamine deficiency in the central nervous system (CNS).
- Previous gene therapy approaches using tyrosine hydroxylase (TH) were limited by cofactor availability and feedback inhibition.
- Effective dopamine restoration requires understanding the complex synthesis and delivery pathways.
Purpose of the Study:
- To identify the optimal gene set for effective dopamine delivery in Parkinson's disease gene therapy.
- To investigate methods for overcoming limitations in dopamine synthesis and release.
- To develop a strategy for sustained and regulated dopamine delivery.
Main Methods:
- Systematic neurobiological investigation of dopamine synthesis biochemical steps.
- Gene transfer of GTP cyclohydrolase I (for BH1 cofactor synthesis), tyrosine hydroxylase (TH), and aromatic L-amino acid decarboxylase (AADC).
- Utilizing in vivo biochemical assays with microdialysis to assess gene function and dopamine levels.
- Employing a complementary strategy involving vesicular monoamine transporter gene transfer.
Main Results:
- Co-expression of GTP cyclohydrolase I and TH enabled L-DOPA production.
- Adding AADC led to feedback inhibition of TH by dopamine.
- Combining vesicular monoamine transporter with AADC allowed L-DOPA conversion, storage, and gradual dopamine release.
- Microdialysis confirmed the quantitative effects of different gene combinations on dopamine delivery.
Conclusions:
- A multi-gene approach is crucial for successful dopamine restoration in PD.
- Overcoming feedback inhibition and ensuring controlled release are key for effective gene therapy.
- The combination of vesicular monoamine transporter and AADC offers a regulated method for sustained dopamine delivery, improving therapeutic potential for Parkinson's disease.